Low paraoxonase and arylesterase plasma activities in Mexican patients with coronary artery disease;Actividades paraoxonasa y arilesterasa bajas en sujetos mexicanos con enfermedad arterial coronaria

Archivos de Cardiologia de Mexico

Volumn 78, Issue 4, 2008, Pages 360-368

  Gamboa, Ricardo ^a   Regalado, Juan Carlos ^a   Huesca Gómez, Claudia ^a   Posadas Romero, Carlos ^a   Paris, Juan Verdejo ^a   Vargas Alarcón, Gilberto ^a   Pérez Méndez, Óscar ^a  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

Coronary heart disease; High density lipoproteins; Mexican population; Paraoxonase 1 polymorphisms

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; PARAOXON; PHENYLACETIC ACID;

ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME SUBSTRATE; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ARYLDIALKYLPHOSPHATASE; CARBOXYLIC ESTER HYDROLASES; CHOLESTEROL, HDL; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; GENOTYPE; HUMANS; MALE; MEXICO; MIDDLE AGED; MYOCARDIAL INFARCTION; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 58149296389     PISSN: 14059940     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. ASSMANN G, SCHULTE H, VON ECKARDSTEIN, A, HUANG Y: High-density lipoprotein cholesterol as a predictor of coronary heart disease risk: the PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996; 124: S11-S20.
2. SCHAEFER EJ, LAMON-FAVA S, ORDOVAS JM, COHON SD, SCHAEFER MM, CASTELLI WP, ET AL: Factors associated with low and elevated plasma high-density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study. J Lipid Res 1994; 35: 871-882.
3. SORENSON RC, BISGAIER CL, AVIRAM M, HSU C, BILLECKE S, LA DU BN: Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity. Arterioscler Thromb Vasc Biol 1999; 19: 2214-2225.
4. MACKNESS M, ARROL S, ABBOTT C, DURRINGTON PN: Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993; 104: 129-135.
5. AVIRAM M, ROSENBLAT M, BISGAIER CL, NEWTON RS, PRIMO-PARMO SL, LA DU BN: Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998; 101: 1581-1590.
6. MACKNESS M, MACKNESS B, DURRINGTON PN, CONNELLY PW, HEGELE RA: Paraoxonase: Biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996; 7: 69-76.
7. LI WF, COSTA LG, RICHTER RJ, HAGEN T, SHIH TM, TWARD A, ET AL: Catalytic efficiency determines the in-vivo efficacy of PONI for detoxifying organophosphorus compounds. Pharmacogenetics 2000; 10: 767-779.
8. IMAI Y, MORITA H, KURIHARA H, SUGIYAMA T, KATO N, EBIHARA A, ET AL: Evidence for association for paraoxonase gene polymorphisms and atherosclerotic disease. Atherosclerosis 2000; 149: 435-442.
9. SHANGERA DK, SHARA N, ASTON CE, KAMBOH MI: Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol 1997; 17: 1067-1073.
10. KARVONEN J, KAUMA H, PAIVANSALO M, KESANIEMI Y: Paraoxonase-1 gene Leu-Met55 and Gln-Arg192 polymorphisms are not associated with carotid artery atherosclerosis in a population-based cohort. Eur J Cardiovasc Prev Rehabil 2004; 6: 511-512.
11. SANGHERA DK, SAHA N, KAMBOH MI: The codon 55 polymorphism in the paraoxonase I gene is not associated with the risk of coronary heart disease in Asian Indians and Chinese. Atherosclerosis 1998; 136: 217-223.
12. ARCA M, OMBRES D, MONTALI A, CAMPAGNA F, MANGIERI E, TANZILLI G, ET AL: PONI L55M polymorphism is not a predictor of coronary atherosclerosis either alone or in combination with Q192R polymorphism in an Italian population. Eur J Clin Invest 2002; 32: 9-15.
13. JARVIK GP, ROZEK LS, BROPHY VH, HATSUKAMI TS, RITCHER RJ, SCHELLENBERG GD, ET AL: Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol 2000; 20: 2441-2447.
14. JARVIK GP, HATSUKAMI TS, CARLSON C, RITCHER RJ, JAMPSA R, BROPHY VH, ET AL: Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscler Thromb Vasc Biol 2003; 23: 1465-1471.
15. MACKNESS B, DAVIES GK, TURKIE W, LEE E, ROBERTS DH, HILL E, ET AL: Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 2001; 21: 1451-1457.
16. ECKERSON HW, ROMSON J, WYTE C, LA DU BN: The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Genet 1983; 35: 214-227.
17. ADKINS S, GAN KN, MODY M, LAD U B: Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993; 52: 598-608.
18. HUMBERT R, ADLER DA, DISTECHE CM, HASSETT C, OMIECINSKI CJ, FURLONG CE: The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993; 3: 73-76.
19. WHEELER JG, KEAVNEY BD, WATKINS H, COLLINS R, DANESH J: Four paraoxonase polymorphism in 11 212 cases of coronary heart disease and 12 786 controls: meta-analysis of 43 studies. Lancet 2004; 363: 389-395.
20. ROJAS-GARCÍA AE, SOLÍS- HEREDIA MJ, PIÑA-GUZMAN L, LÓ PEZ-CARRILLO L, QUINTANILLA-VEGA B: Genetic polymorphism and activity of PON1 in a Mexican population. Toxicol Appl Pharmacol 2005; 205: 282-289.
21. GAMBOA R, ZAMORA J, RODRIGUEZ-PEREZ JM, FRAGOSO JM, CARDOSO G, POSADAS-ROMERO C, ET AL: Distribution of paraoxonase PON1 gene polymorphisms in Mexican populations. Its role in the lipid profile. Exp Mol Pathol 2006; 80: 85-90.
22. VARGAS-ALARCÓN G, ZAMORA J, SÁNCHEZ-GARCÍA S, RODRIGUEZ- PÉREZ, M, CARDOSO G, POSADAS-ROMERO C: Angiotensin-I-converting enzyme (ACE) insertion/deletion polymorphism in Mexican patients with coronary heart disease. Association with the disease but not with lipids levels. Exp Mol Pathol 2006; 81: 131-135.
23. DELONG DM, DELONG ER, WOOD PD, LIPPEL K, RIFKIND B: A comparison of methods for the estimation of plasma low- and very low-density lipoprotein cholesterol. The Lipid Research Clinics Prevalence Study. JAMA 1986; 256: 2372-2377.
24. ECKERSON HW, WYTE CM, LA DU BN: The human serum paraoxonase/arylesterease polymorphism. Am J Human Genet 1983; 35: 1126-1138.
25. GAN KL, SMOLEN A, ECKERSON HW, LA DU BN: Protein purification of human serum paraoxonase/ arylesterease. Evidence for one esterease catalyzing both activities. Drug Metab Dispos 1991; 19: 100-106.
26. MILLER SA, DYKES DD, POLESKY HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 1: 1215.
27. MOTTI C, DESSY M, GNASSO A, IRACE C, INDIGENO P, ANGELUCCI CB, ET AL: A multiplex PCR-based DNA assay for the detection of paraoxonase gene cluster polymorphism. Atherosclerosis 2001; 158: 35-40.
28. BROWNE RW, KOURY ST, MARION S, WILDING G, MUTI P, TREVISAN M: Accuracy and biological variation of human serum paraoxonase I activity and polymorphism (Q192R) by kinetic enzyme assay. Clin Chem 2007; 53: 310-317.
29. BLATTER MC, JAMES RW, MESSMER S, BARJA F, POMETTA D: Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem 1993; 211: 871-879.
30. AYUB A, MACKNESS MI, ARROL S, MACKNESS B, PATEL J, DURRINGTON PN: Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol. 1999; 19: 330-335.
31. SVIRIDOV D, NESTEL PJ: Genetic factors affecting HDL levels, structure, metabolism and function. Curr Opin Lipidol 2007; 18: 157-163.
32. WATANABE H , SÖDERLUND S, SORO- PAAVONEN A, HIUKKA A, LEINONEN E, ALAGONA C, ET AL: Decreased high-density lipoprotein (HDL) particle size, preß-, and large HDL subspecies concentration in Finnish low-HDL families: relationship with intima-media thickness. Arterioscler Thromb Vasc Biol 2006; 26: 897-902.
33. MORGAN J, CAREY C, LINCOFF A, CAPUZZI D: High-density lipoprotein subfractions and risk of coronary artery disease. Curr Atheroscler Rep 2004; 6: 359-365.
34. MCELEVEEN J, MACKNESS MI, COLLEY CM, PEARD T, WARNER S, WALKER CH: Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem 1986; 32: 671-673.
35. MACKNESS B, MACKNESS MI, ARROL S, TURKIE W, DURRINGTON PN: Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high-density lipoprotein against low-density lipoprotein oxidative modification. FEBS Lett 1998; 423: 57-60.
36. RUIZ J, BLANCHE H, JAMES RW, GARIN MJ, VAISSE C, CHARPENTIER G, ET AL: Gln-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 1995; 346: 869-887.
37. MACKNESS MI, HARTY D, BHATNAGAR D, WINOCOUR TH, ARROL S, ISHOLA M, ET AL: Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991; 86: 193-199.
38. DANTOINE TF, DEBORD J, CHARMES JP, MERLE L, MARQUET P, LACHATRE G, ET AL: Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol 1998; 9: 2082-2088.
39. JARVIK GP, TSAI NT, MCKINSTRY LA, WANI R, BROPHY V, RITCHER RJ, ET AL: Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler Thromb Vasc Biol 2002; 22: 1329-1333.
40. SENTI M, TOMAS M, ANGLADA R, ELOSUA R, MARRUGAT J, COVAS MI, ET AL: Interrelationship of smoking, paraoxonase activity and leisure-time physical activity: a population based-study. Eur J Intern Med 2003; 14: 178-184.
41. KLEEMOLA P, FREESE R, JAUHIAINEN M, PAHLMAN R, ALFTHAN G, MUTANEN M: Dietary determinants of serum paraoxonase activity in healthy humans. Atherosclerosis 2002; 160: 425-432.